Corgenix Medical Corporation has been recognized for outstanding research presented at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection," presented at the conference by Corgenix Research Associate Abby Jones, M.S.
The Best Annual Meeting Abstract Award is given by the AACC Critical and Point of Care Testing Division in recognition of outstanding research for abstracts submitted and posters presented at the AACC annual meeting.
"We're pleased to accept this prestigious award, and we must also recognize our academic, research and industry partners at the Viral Hemorrhagic Fever Consortium who have helped to make this possible," said Douglass Simpson, Corgenix President and CEO. "We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa and other biologic agents. Rapid, accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats."
Corgenix and the VHFC were recently awarded a three-year, $2.9 million National Institutes of Health grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV(R) rapid diagnostic test for the Lassa fever virus.
Given the current Ebola outbreak in West Africa, the largest ever recorded, Simpson said it's clear that point-of-care testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola and Marburg.
On Thursday, July 31, 2014, Corgenix also presented an oral abstract titled "Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone." This first-ever oral abstract for Corgenix was discussed during the AACC morning symposia titled "Infected: Innovative Ideas in Laboratory Medicine for Acute and Chronic Infections."
The study was conducted to better identify and treat patients with Lassa, which can be difficult to distinguish from other illnesses such as malaria. Study results were presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry.
The Best Annual Meeting Abstract Award is given by the AACC Critical and Point of Care Testing Division in recognition of outstanding research for abstracts submitted and posters presented at the AACC annual meeting.
"We're pleased to accept this prestigious award, and we must also recognize our academic, research and industry partners at the Viral Hemorrhagic Fever Consortium who have helped to make this possible," said Douglass Simpson, Corgenix President and CEO. "We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa and other biologic agents. Rapid, accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats."
Corgenix and the VHFC were recently awarded a three-year, $2.9 million National Institutes of Health grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV(R) rapid diagnostic test for the Lassa fever virus.
Given the current Ebola outbreak in West Africa, the largest ever recorded, Simpson said it's clear that point-of-care testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola and Marburg.
On Thursday, July 31, 2014, Corgenix also presented an oral abstract titled "Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone." This first-ever oral abstract for Corgenix was discussed during the AACC morning symposia titled "Infected: Innovative Ideas in Laboratory Medicine for Acute and Chronic Infections."
The study was conducted to better identify and treat patients with Lassa, which can be difficult to distinguish from other illnesses such as malaria. Study results were presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry.